Kinoxis Therapeutics raises $6.75M in equity and $2.5M grant to advance dementia agitation treatments through clinical trials, with results expected in 2027.
Amount Raised
A$6.75 Million
Round Type
Seed
MelbourneBiotechnologyHealth CareTherapeuticsInvestors
Description
Kinoxis Therapeutics, a dementia biotech company, has secured $6.75 million in equity funding led by Main Sequence Ventures, along with a $2.5 million government grant from Australia's Medical Research Future Fund. The total $9.25 million will fund clinical trials for drugs targeting agitation and pain associated with dementia. The company's lead candidate, KNX100, is in Phase 2 trials with initial results expected in mid-2027.
Quick answer
Kinoxis Therapeutics raised A$6.75 Million in a Seed round, dated September 23, 2026. Investors: UniSuper, Uniseed, Stoic Vc, Sydney Uni, Avicella Capital and Main Sequence Ventures. Kinoxis Therapeutics is based in Melbourne, Victoria, Australia.
- How much did Kinoxis Therapeutics raise?
- Kinoxis Therapeutics raised A$6.75 Million in a Seed round on September 23, 2026.
- Who invested in Kinoxis Therapeutics?
- UniSuper, Uniseed, Stoic Vc, Sydney Uni, Avicella Capital and Main Sequence Ventures are named as investors in this round.
- What does Kinoxis Therapeutics do?
- Kinoxis Therapeutics is a dementia biotech company developing drugs for agitation, pain, and other symptoms associated with dementia.
- Where is Kinoxis Therapeutics based and how big is it?
- Kinoxis Therapeutics is based in Melbourne, Victoria, Australia. Fundz records about 2 employees.
- Who are the decision-makers at Kinoxis Therapeutics?
- Fundz holds 3 contacts at Kinoxis Therapeutics, including the Chief Executive Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Kinoxis Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- BioVie raised $4.7M (Post-IPO Equity) on November 6, 2026.
- Alethio raised $90M (Series A) on November 5, 2026.
- MyoPax raised an undisclosed amount (Pre-Seed) on November 4, 2026.
- Biograil raised $22M on November 4, 2026.
- Emvena Therapeutics raised an undisclosed amount (Seed) on November 4, 2026.
- Thryv Therapeutics raised $30M (Series B) on November 3, 2026.
Who to call at Kinoxis Therapeutics, and when
A new round usually means Kinoxis Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Kinoxis Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kinoxis Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kinoxis Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kinoxis Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Kinoxis Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.